Mifepristone is a widely used agent in obstetrics and gynecology, extending far beyond the termination of early pregnancy to become a key option in managing emergency contraception, uterine fibroids, and endometriosis. While this prescription is familiar in daily practice, its very frequency can lead to oversight of critical details such as dosage variations, risk boundaries, and off-label use. This article addresses the ten most common clinical dilemmas, clarifying standard protocols, contraindications, and monitoring principles to define the proper use of this "old friend."

Q1: What is the correct dosage for emergency contraception? Is it the same as "medical abortion"?

☞ Answer: The dosage and mechanism are completely different; they must not be confused.

This is the most common point of confusion. For emergency contraception, the standard dose of Mifepristone is 25 mg or 10 mg, taken as a single oral dose within 72 hours of unprotected intercourse. Its primary mechanism is to inhibit or delay ovulation and interfere with fertilization; this dose is far below the threshold required for anti-gestational (abortifacient) effects.

In contrast, the standard regimen for terminating early pregnancy (medical abortion) involves a single dose of 200 mg, followed by Misoprostol 24–48 hours later. There is a fundamental difference in both dosage and mechanism. When prescribing and counseling patients, it is crucial to distinguish between these uses to avoid misunderstanding.

Q2: Can women with a history of cesarean section (scarred uterus) use it for pregnancy termination?

☞ Answer: It can be used, but it is by no means an "optimal" choice, and risks require high vigilance.

Under strict evaluation—meeting criteria for gestational age and uterine scar condition—Mifepristone combined with Misoprostol may be used for early pregnancy termination in women with a history of cesarean section. However, it should never be considered safer than surgery. The drug label explicitly warns of rare cases of uterine rupture associated with use in patients having uterine scars. Therefore, it must be performed in a medical facility equipped for emergency care, under the close supervision of experienced physicians, with thorough risk assessment and informed consent.

Q3: How effective is it for treating uterine fibroids? Will they recur after discontinuation?

☞ Answer: The effect on volume reduction is clear, but the efficacy is temporary.

For symptomatic patients (especially perimenopausal women or those preparing for surgery), a daily dose of 10–12.5 mg for 3–6 months effectively reduces fibroid volume (by an average of 30%–50%), significantly decreases menstrual flow, and improves anemia. However, it must be recognized that the volume reduction is temporary. Upon discontinuation, fibroid size typically returns to pre-treatment levels. Therefore, it is primarily indicated for:

Preoperative preparation to reduce volume and vascularity.

Perimenopausal women transitioning to menopause.

Intermittent therapy to control symptoms and postpone surgery.

Q4: If ultrasound shows uneven endometrial thickening, is it caused by the drug or pathology?

☞ Answer: It could be PAEC (Progesterone Receptor Modulator Associated Endometrial Changes), a benign and reversible drug-related change.

Long-term use (usually ≥3 months) of SPRMs like Mifepristone can lead to PAEC. Ultrasound may show endometrial thickening, heterogeneous echoes, or cystic changes, which are easily misdiagnosed as endometrial hyperplasia or polyps.

Key Point: PAEC is a specific, benign, reversible change related to the drug's action; its pathological features differ from typical endometrial hyperplasia. Asymptomatic PAEC does not require diagnostic curettage. It is recommended to re-evaluate with ultrasound 1–3 months after discontinuation, as the endometrium usually recovers naturally. Avoid over-treating PAEC based on misdiagnosis.

Q5: For incomplete abortion, can it be used to avoid a D&C (curettage)?

☞ Answer: This is off-label use and requires careful assessment and full informed consent.

In cases of retained products of conception (especially when small and with poor blood flow), clinical practice sometimes uses Mifepristone (e.g., 25–50 mg once or twice daily for several days) to promote expulsion and avoid a second curettage. However, this is strictly off-label. Decisions must be individualized based on the size of the residue, hCG levels, and bleeding status. Patients must be fully informed about the nature of off-label use, potential benefits, and risks before proceeding.

Q6: What must be monitored before and during treatment?

☞ Answer: Liver function is the essential safety baseline.

Although severe liver injury is rare, Mifepristone has been associated with elevated serum transaminases (ALT/AST). Therefore, assessing baseline liver function prior to treatment is mandatory. For patients requiring long-term therapy (≥3 months), regular monitoring (e.g., every 1–3 months) is recommended. If transaminases rise significantly, the drug should be discontinued promptly for evaluation.

Q7: What are the absolute "red lines" (Contraindications)?

☞ Answer: The following are explicit contraindications that must be strictly observed:

Chronic adrenal failure.

Recent (within 1 week) or current systemic glucocorticoid therapy.

Hereditary porphyria.

Confirmed or suspected ectopic pregnancy (it is ineffective for ectopic pregnancy and can delay treatment).

Bleeding disorders or concurrent anticoagulant therapy.

Severe cardiac, hepatic, or renal insufficiency.

Hypersensitivity to Mifepristone or any excipients.

Q8: With which common drugs does it "conflict" (Drug Interactions)?

☞ Answer: Caution is required regarding interactions with the CYP3A4 enzyme.

Mifepristone is metabolized mainly by hepatic CYP3A4 and is itself a strong inhibitor of CYP3A4.

Interaction Warning: Concomitant use with drugs metabolized by CYP3A4 (i.e., CYP3A4 substrates, such as certain statins, sedatives, and immunosuppressants) may significantly increase their plasma concentration and toxicity risk. Concurrent use with strong CYP3A4 inducers (such as Rifampicin, Carbamazepine, St. John's Wort) may reduce the efficacy of Mifepristone.

Clinical Advice: Always inquire thoroughly about a patient’s concomitant medications when prescribing, exercising particular caution with drugs that have a narrow therapeutic window.

Q9: How is it used for Endometriosis/Adenomyosis?

☞ Answer: It is an effective pharmaceutical option for pain relief.

Via its anti-progestin action, Mifepristone effectively inhibits the growth of ectopic endometrium and reduces inflammation, thereby significantly alleviating pain associated with endometriosis/adenomyosis. The common dose is 5–12.5 mg daily for 3–6 months. It can be used as follow-up maintenance therapy after GnRH-a treatment or as an alternative for patients unwilling to use GnRH-a. Long-term use requires monitoring for endometrial changes.

Q10: What is the standard protocol for terminating early pregnancy? What is the upper limit of gestational age?

☞ Answer: The protocol must be precise, and the gestational limit is clearly defined.

Standard Protocol: A single oral dose of Mifepristone 200 mg, followed by Misoprostol 800 μg administered vaginally or buccally 24–48 hours later. This is the classic, clinically validated regimen.

Gestational Limit: The approved indication in China is strictly for terminating intrauterine pregnancies up to ≤70 days (i.e., within 10 weeks). Use beyond this gestational age falls outside the scope of approval and guideline recommendations and should be considered off-label, requiring extreme caution and thorough risk-benefit assessment.

Conclusion:

Mifepristone is a precise "double-edged sword." It is a powerful tool in family planning and benign disease management, but its application hinges on "precision": precise indications, precise dosing, precise monitoring of potential risks (PAEC, liver damage, drug interactions), and precise communication with patients. We hope these "Ten Q&As" help clinicians navigate the use of this "versatile player" more safely and confidently.

This article provides healthcare professionals with drug knowledge and clinical references and does not constitute medical advice, treatment recommendations, or official guidelines. Non-healthcare professionals should not reference or disseminate this content. The platform assumes no responsibility for any consequences arising from the use of this information by non-professionals.

Editor: Lily